Molecular MOLN 深 滬
等待開盤 09-17 09:30:00 美东时间
3.92
-0.280
-6.67%
華盛通- 最 高4.02
- 今 開3.84
- 成交量 2099股
- 最 低 3.84
- 昨 收 4.20
- 總市值 1.50亿
- 52周最高 5.36
- 市盈率 靜 --
- 換手率 0.01%
- 52周最低 3.53
- 委 比 -77.78%
- 總股本 3830.52万
- 歷史最高 32.04
- 量 比 1.54
- 振 幅 4.29%
- 歷史最低 3.32
- 每 手 1
- 風險率 0.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara
Pixclara® is the first FDA-approved FET-PET imaging drug for glioma, aiding in differentiating recurrent or progressive glioma from treatment-related changes. It addresses a significant unmet need and is recommended in international guidelines like NCCN. Pixclara expands Telix's precision medicine portfolio, enhancing diagnostics and targeted therapies. Gliomas are the most common brain cancer, with 24,000 new cases annually in the U.S. Pixclara...
09-14 10:30
Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
Erasca, Inc. announced that updated monotherapy clinical data for ERAS-0015 and nonclinical combination data with ERAS-4001 will be presented at the 38th EORTC-NCI-AACR Symposium. ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, a pan-KRAS inhibitor, show promise in treating RAS/MAPK pathway-driven cancers. The oral presentation will share expanded AURORAS-1 trial results, while the poster will highlight synergy in KRAS G12X models. Erasca aim...
09-10 12:00
IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development
IN8bio announced the appointment of Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development. With over 20 years of experience in γδ T cell biology and T cell engagers (TCEs), Dr. Polyakova brings significant expertise in oncology, immunology, and cell therapies. She previously served as Chief Scientific Officer at LAVA Therapeutics and LIfT Biosciences, and was Scientific Founder and Head of Discovery at Adaptate Biotherapeutic...
09-09 12:00
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
Monte Rosa Therapeutics announced that its collaborator Novartis has initiated a Phase 2 clinical study for MRT-6160 (DDY391), a molecular glue degrader targeting VAV1, in patients with Sjögren’s disease. This marks the first of several expected studies for MRT-6160 under a global exclusive license agreement between Monte Rosa and Novartis. Monte Rosa will receive a $50 million milestone payment upon the first patient visit. MRT-6160 has shown po...
09-08 11:00
VERAXA Biotech Appoints Raju Willener as Chief Financial Officer
VERAXA Biotech AG has appointed Raju Willener as Chief Financial Officer, effective immediately. With over three decades of global capital markets and corporate finance experience, Willener will support the advancement of the Company’s BiTAC® platform and oncology pipeline. Willener previously served as CFO at Exentis Group AG and has held senior roles in investment banking, asset management, and corporate finance across the U.S., Europe, and Asi...
09-04 11:00
iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference
Insight Molecular Diagnostics Inc. (IMDX) announced its participation in the Lake Street Capital Markets 10th Annual Best Ideas Growth "BIG10" Conference on September 10, 2026, in New York. CEO Josh Riggs and CFO Andrea James will attend, offering one-on-one meetings with investors. The event will take place at the Metropolitan Club. Investors interested in meeting IMDX management should contact their Lake Street sales representative. Insight Mol...
09-02 12:00
Telix Appoints David Gill as Chair
David Gill appointed as Chair of Telix Pharmaceuticals Board, effective immediately. He joined Telix in May 2026 as a Non-Executive Director with the intention of becoming Chair. Dr. Mark Nelson, interim Chair, will continue as a Non-Executive Director. Gill brings over 35 years of experience in life sciences, financial leadership, and corporate strategy. Telix is a global radiopharmaceutical company advancing targeted theranostics for cancer tre...
08-31 22:21
Molecular Partners GAAP EPS of -CHF0.70
Molecular Partners press release (MOLN): 1H GAAP EPS of -CHF0.70. Cash position of CHF 67.9 million (USD ~84 million) as of June 30, 2026, expected to fund operations into late 2027. More on Molecular...
08-25 19:54
Molecular Partners Q2 EPS $(0.89) Misses $(0.45) Estimate
Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(0.89) per share which missed the analyst consensus estimate of $(0.45) by 95.56 percent. This is a 31.34 percent decrease over losses of $(0.67) per share from the same period last year.
08-25 18:15
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors
Parabilis Medicines announced the appointment of Craig L. Tendler, M.D., to its Board of Directors. Dr. Tendler, a seasoned oncology expert with over 30 years of experience at Johnson & Johnson, will also continue his role as a scientific advisor. His extensive background in clinical development and regulatory approvals is expected to significantly benefit Parabilis as it advances its lead drug, zolucatetide, and expands its pipeline of innovativ...
08-25 11:00
